Chamberlain Paul, Hammond David S, Bradley Arthur, Arumugam Baskar, Richdale Kathryn, McNally John, Hunt Chris, Young Graeme
CooperVision, Pleasanton, California.
Visioncare Research, Farnham, Surry, United Kingdom.
Optom Vis Sci. 2025 May 1;102(5):353-358. doi: 10.1097/OPX.0000000000002244. Epub 2025 Mar 24.
This 7-year clinical study assessed the impact of age and number of years of myopia control treatment with MiSight 1 day (omafilcon A; CooperVision, Inc., Pleasanton, CA) dual-focus contact lenses on post-treatment eye growth and myopia progression. Growth and progression after treatment were ceased and returned to age-normal levels retaining prior accrued treatment gains.
This study aimed to assess eye growth and refractive changes after cessation of prolonged myopia control treatment with a dual-focus contact lens.
Eighty-three subjects completing a 6-year clinical trial of a dual-focus myopia control contact lens (MiSight 1 day) continued into a follow-on 1-year "wash-out" phase in which all subjects were fit with a single-vision contact lens (Proclear 1 day, omafilcon A; CooperVision, Inc.). Right and left eye data were analyzed from 38 subjects with 6 years of prior treatment (T6) and 40 receiving treatment during study years 4 to 6 (T3). Axial length and cyclopleged spherical equivalent refractive errors were monitored annually for 7 years. Expected axial growth and myopia progression during years 4 to 7 if treatment had not been started were estimated by extrapolating growth of untreated myopic control eyes collected during years 1 to 3 using population-based estimates of age effects on growth rates.
During the untreated year 7, annualized axial growth and refractive changes were 0.09 ± 0.09 (T3) and 0.10 ± 0.10 mm/y (T6), and -0.23 ± 0.36 (T3) and -0.21 ± 0.40 D/y (T6), respectively, each slightly greater than observed during the previous year of treatment (0.07 ± 0.12 [T3] and 0.08 ± 0.07 mm [T6], and -0.04 ± 0.34 [T3] and -0.13 ± 0.42 D [T6]). Year 7 progression was less for the older (11 to 12 at baseline, -0.17 ± 0.40 D/0.05 ± 0.07 mm) than the younger (8 to 10 at baseline, -0.26 ± 0.36 D/0.13 ± 0.10 mm) subgroup. Years in treatment (3 vs. 6) did not influence post-treatment growth or progression.
A cessation study following 3 or 6 years of myopia control treatment with the dual-focus myopia control contact lens found axial growth and myopia progression rates similar to those expected of untreated myopic eyes at these ages. This finding reveals that accrued treatment gains were retained and neither amplified nor diminished after cessation of treatment.
这项为期7年的临床研究评估了年龄以及使用MiSight 1天（奥马菲康A；库博光学公司，普莱森顿，加利福尼亚州）双焦点隐形眼镜进行近视控制治疗的年数对治疗后眼睛生长和近视进展的影响。治疗后的生长和进展停止，并恢复到年龄正常水平，保留了之前累积的治疗效果。
本研究旨在评估使用双焦点隐形眼镜进行长期近视控制治疗停止后眼睛的生长和屈光变化。
83名完成双焦点近视控制隐形眼镜（MiSight 1天）6年临床试验的受试者进入为期1年的后续“洗脱”阶段，在此阶段所有受试者佩戴单焦点隐形眼镜（Proclear 1天，奥马菲康A；库博光学公司）。分析了38名接受过6年前期治疗（T6）的受试者和40名在研究第4至6年接受治疗（T3）的受试者的右眼和左眼数据。连续7年每年监测眼轴长度和睫状肌麻痹下的等效球镜屈光不正。如果未开始治疗，通过使用基于人群的年龄对生长率影响的估计值，外推第1至3年收集的未治疗近视对照眼的生长情况，来估计第4至7年预期的眼轴生长和近视进展。
在未治疗的第7年，年化眼轴生长和屈光变化分别为0.09±0.09（T3）和0.10±0.10mm/年（T6），以及-0.23±0.36（T3）和-0.21±0.40D/年（T6），均略高于上一年治疗期间观察到的值（0.07±0.12 [T3]和0.08±0.07mm [T6]，以及-0.04±0.34 [T3]和-0.13±0.42D [T6]）。年龄较大的亚组（基线时11至12岁，-0.17±0.40D/0.05±0.07mm）在第7年的进展小于年龄较小的亚组（基线时8至10岁，-0.26±0.36D/0.13±0.10mm）。治疗年数（3年与6年）不影响治疗后的生长或进展。
一项在使用双焦点近视控制隐形眼镜进行3年或6年近视控制治疗后的停药研究发现，眼轴生长和近视进展率与这些年龄未治疗的近视眼睛预期的相似。这一发现表明，累积的治疗效果得以保留，治疗停止后既未放大也未减弱。
